On December 15, 2020, AbCellera Biologics Inc. (“AbCellera”) announced the closing of its initial public offering of common shares (“Common Shares”) and listing on the NASDAQ Global Select Market (the “IPO”) under the symbol “ABCL”. In connection with the IPO, AbCellera issued a total of 27,772,500 Common Shares (which included an additional 3,622,500 Common Shares issued pursuant to the exercise in full of the over-allotment option by the Underwriters (as defined below) granted to them pursuant to the underwriting agreement) at a price of US$20 per Common Share for total aggregate gross proceeds to AbCellera of approximately US$555 million. Credit Suisse Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, Berenberg Capital Markets LLC, SVB Leerink LLC abd BMO Capital Markets Corp. acted as underwriters in the IPO (the “Underwriters”).
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Osler, Hoskin & Harcourt LLP advised the Underwriters with a team consisting of Shahir Guindi, Trevor Scott, Jeremy Brisset, Ian Morrison (Corporate), Tara Folk (Emerging and High Growth Companies) and Tim Hughes (Tax).